Alimera Sciences (NASDAQ:ALIM) Upgraded at ValuEngine

ValuEngine upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a hold rating to a buy rating in a report released on Tuesday morning, ValuEngine reports.

A number of other equities analysts have also weighed in on the company. Zacks Investment Research upgraded Alimera Sciences from a sell rating to a hold rating in a research note on Friday, November 8th. B. Riley set a $30.00 target price on Alimera Sciences and gave the stock a buy rating in a research note on Monday, September 30th. Finally, HC Wainwright restated a buy rating and issued a $15.00 target price on shares of Alimera Sciences in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Alimera Sciences has a consensus rating of Buy and a consensus price target of $26.25.

ALIM stock opened at $6.79 on Tuesday. Alimera Sciences has a 12 month low of $2.96 and a 12 month high of $18.15. The firm’s fifty day simple moving average is $2.47 and its 200-day simple moving average is $1.13.

Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). The business had revenue of $12.85 million for the quarter, compared to analysts’ expectations of $12.75 million. On average, research analysts expect that Alimera Sciences will post -2.58 EPS for the current fiscal year.

In other Alimera Sciences news, CEO Richard S. Eiswirth, Jr. purchased 100,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average price of $5.21 per share, for a total transaction of $521,000.00. Also, Director John Snisarenko purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average price of $4.95 per share, with a total value of $49,500.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $49,500. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 113,000 shares of company stock valued at $585,830. Insiders own 14.60% of the company’s stock.

An institutional investor recently raised its position in Alimera Sciences stock. Renaissance Technologies LLC grew its holdings in Alimera Sciences Inc (NASDAQ:ALIM) by 13.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,128,404 shares of the biopharmaceutical company’s stock after buying an additional 130,414 shares during the quarter. Renaissance Technologies LLC owned 1.59% of Alimera Sciences worth $1,004,000 as of its most recent SEC filing.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Featured Story: Understanding Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.